

11-15-07

PATENT APPLICATIONIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Akerman et al.

Serial No.: 10/591,214 V Group Art Unit No.: 1625

Filed: August 28, 2006 Examiner: Not Yet Assigned

For: COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND
METHODS FOR USE IN TREATING METABOLIC DISORDERS

Docket No.: A-988-US-PCT

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Examiner:

As a means of complying with the duty of disclosure under 37 CFR §§ 1.97 and 1.98, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

Applicants make no determination of relevancy with respect to the references submitted herewith and request the Examiner to make an independent determination of relevance and/or materiality of the references.

The Supplementary Partial European Search Report submitted herewith was completed on September 7, 2007, for a counterpart European application (EP 05723623). The two patent documents submitted herewith (WO 02/100403 and WO 02/062774) have not previously been submitted in this application.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Identification of the listed references is not to be construed as an Admission by Applicants or attorney for Applicants that such references are available or qualify

EXPRESS MAIL CERTIFICATE

'Express Mail' mail labeling number: EL 732554029 US

Date of Deposit: November 13, 2007

I hereby certify that this paper or less is being deposited with the United States Postal Service "Express Mail/Post Office&6 Addressess" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DeeDee Sutherland
 Printed Name

 Signature

as "prior art" against the subject application. Applicants reserve the right to remove any such reference which the Patent and Trademark Office may cite against the subject application.

Applicants request consideration of this information and passage of the application to issue.

No fee should be required for the filing of this information disclosure statement. However, in the event any fee is due the Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

21069

Please send all future correspondence to:
US Patent Operations/BPF
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799



Bernard P. Friedrichsen
Attorney/Agent for Applicant(s)
Registration No.: 44,689
Phone: (805) 447-0628
Date: November 13, 2007